The lion’s mane mushroom has a long and complex history of being used as a supplement as part of a healthy diet.
The International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) has launched today to push for the rescheduling of psilocybin across the globe.
The world’s first controlled study exploring the use of ketamine-assisted psychotherapy for the treatment of alcohol use disorder (AUD) has shown positive results.
The Canadian Government has amended regulation in order to allow patients to access psychedelic medicines such as psilocybin and MDMA.
Albert Labs has highlighted that the UK’s new guidance on Real-World data will accelerate access to psychedelic treatments.
A review has shown that ketamine therapy is able to rapidly reduce symptoms of depression and suicidal thoughts in the short-term.
The groundbreaking study will now be expanded to explore the use of ketamine for treating binge eating disorder, compulsive sexual behaviour and internet gaming disorder.
A new collaboration is aiming to develop psychedelic medicines to address the unique needs of people living with a variety of mental health conditions.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
One company is providing investors with the opportunity to contribute to novel mental health care solutions by participating in the growth of companies in the psychedelics...
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
